Axatilimab Clinical Trials

4 actively recruiting trials across 4 locations

Also known as: Ab969.g2, Anti-M-CSFR Monoclonal Antibody SNDX-6352, C24H23FN4O3, SNDX 6352, SNDX-6352, SNDX6352, SNDX6532, UCB6352

Filter by location:

Boston, Massachusetts1 trial

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Beth Israel Deaconess Medical Center

Phase 1

Detroit, Michigan1 trial

Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Karmanos Cancer Institute

Phase 2

Columbus, Ohio1 trial

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2

Portland, Oregon1 trial

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

OHSU Knight Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.